Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sunshine Bill Gains Momentum From PhRMA But Time May Be Running Short

Executive Summary

With an endorsement by the Pharmaceutical Research and Manufacturers America and three drug companies, momentum is building for Senate legislation to set up a federal reporting program for drug and device companies to disclose their gifts to physicians

You may also be interested in...



Revised Sunshine Act Pre-empts State Reporting Duplications, Not Differences

Senate Finance Committee Investigative Counsel Christopher Armstrong said the goal of pre-emption provisions in the latest version of the Physician Payment Sunshine Act is to create neither a floor nor ceiling for state reporting requirements, but merely to prevent duplicate reporting on state and federal levels

Revised Sunshine Act Pre-empts State Reporting Duplications, Not Differences

Senate Finance Committee Investigative Counsel Christopher Armstrong said the goal of pre-emption provisions in the latest version of the Physician Payment Sunshine Act is to create neither a floor nor ceiling for state reporting requirements, but merely to prevent duplicate reporting on state and federal levels

Some Clouds For PhRMA In Sunshine Act: Revised Bill Loosens Pre-emption

Sens. Herb Kohl, D-Wis., and Chuck Grassley, R-Iowa, have narrowed state pre-emption provisions in their latest Physician Payments Sunshine Act

Related Content

UsernamePublicRestriction

Register

PS049681

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel